News-Medical.Net on MSN14h
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To request a 1x1 meeting with management, please contact your ...
Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the publication of a ...
That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found ...
Travere Therapeutics, Inc., today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring ...
First for Women on MSN20h
Mia Hamm on Her Brother's Death + Advocating for Others (EXCLUSIVE)While many recognize Mia Hamm as a legendary soccer player and two-time Olympic gold medalist, she has also become a ...
Catherine Melfi; Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer; Omeros Corp Nadia Dac; Vice President, Chief Commercial Officer; Omeros Corp Good afternoon, and ...
Research led by Children's Hospital of Fudan University in China has found that a gene called pancreatic progenitor cell ...
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback